{"nctId":"NCT03196973","briefTitle":"Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Acute Otitis Externa","startDateStruct":{"date":"2017-07-22","type":"ACTUAL"},"conditions":["Acute Otitis Externa"],"count":493,"armGroups":[{"label":"DF289 plus DF277","type":"EXPERIMENTAL","interventionNames":["Drug: DF289 plus DF277"]},{"label":"DF289","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: DF289"]},{"label":"DF277","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: DF277"]}],"interventions":[{"name":"DF289 plus DF277","otherNames":["Antibiotic and Corticosteroid"]},{"name":"DF289","otherNames":["Antibiotic"]},{"name":"DF277","otherNames":["Corticosteroid"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Uncomplicated AOE of less tan 21 days, defined as a total symptom score of at least 2 for otalgia, 2 for edema and 1 for otorrhea\n* Brighton Grading of II or III\n* Culture-based diagnosis of acute bacterial otitis externa\n* Willingness to refrain from swimming through end of the study\n\nExclusion Criteria:\n\n* Previous episode of AOE within 4 weeks prior to enrollment, or 2 or more episodes of AOE within 6 months prior to the enrollment.\n* Tympanic membrane perforation\n* Any condition or situation likely to cause the patient to be unable or unwilling to comply with study treatment or attend all study visits\n* Any condition in the patient or parent/guardian that, in the judgment of the principal investigator, could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Months","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Therapeutic Cure (Clinical + Microbiological Cure)","description":"Therapeutic cure will be considered achieved if edema, otalgia and otorrhea are resolved with no further requirement of antimicrobial therapy and bacteriological response is Eradication or Presumed Eradication","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to End of Pain","description":"First day on which there is no use of analgesics, the pain score is zero and remains zero until end of study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"5.9","spread":null},{"groupId":"OG002","value":"7.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":196},"commonTop":["headache","ear pain","application site pain","tachycardia","ear pruritus"]}}}